Resumen de Evaluación económica del tratamiento de la hipertensión arterial leve a moderada con antagonistas de angiotensina II (ARA II) en España
Carlos Calvo Gómez, José Enrique López Paz, Paloma González García, Almudena del Castillo
A retrospective cost-efficacy (CE) analysis was carried out with Spanish costs (purchase costs, retail price VAT included, of the year 2004 in Euros), from the perspective of the National Health System, using results from a clinical trial (n = 578) during 8 weeks that compared the efficacy (% of patients with peripheral arterial disease under control) of fixed doses of 4 ARA II: olmesartan, losartan, valsartan and irbesartan in patients with mild-moderate arterial hypertension. Olmesartan was efficient in 56.0% of patients versus 41.7%*, 32.6%* and 52.1% with losartan, valsartan and irbesartan, respectively (* significant differences). Olmesartan presented, for the same acqusition cost, greater efficacy and lower cost per patient controlled. A sensitivity analysis was carried out by modifying the efficacy up to the CE ratio for olmesartan. The results were robust for losartan and valsartan, and sensitive for irbesartan. Olmesartan showed a better pharmacoeconomic profile than losartan, valsartan and irbesartan for the short-term treatment of mild-moderate arterial hypertension in Spain
